Findings from a recent study suggests that clinical and genetic factors affecting warfarin dose requirements differ by race.
The Food and Drug Administration (FDA) announced that Factive (gemifloxacin mesylate; LG Life Sciences) is currently in shortage.
Meropenem has been approved by the Food and Drug Administration (FDA) for the treatment of abdominal infections in infants less than 3 months old.
Amgen announced pooled data from two Phase 3 trials evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis.
Pfizer announced that the Food and Drug Administration (FDA) has approved Rapamune (sirolimus), the first drug approved to stabilize lung function in patients with lymphangioleiomyomatosis (LAM).
Merck has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for grazoprevir/elbasvir 100mg/50mg for the treatment of adults with chronic hepatitis C genotypes 1, 4, or 6 infection
The innate lymphoid cell has demonstrated different immune activities in males vs. females, researchers from the Northwestern Medicine lab have found.
Researchers have discovered that the antiviral interferon-lambda can tighten the blood-brain barrier, protecting the brain from invading viruses.
Preliminary findings from a study funded by the the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), indicate that HIV-infected individuals have a considerably reduced risk of developing AIDS or other serious illnesses if they initiate treatment with antiretroviral medications when their CD4+ T-cell count is higher, rather than waiting until this cell count drops to lower levels.
NeuroMetrix announced the launch of the Quell device for the treatment of chronic pain in patients with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia, and osteoarthritis pain.
The Food and Drug Administration (FDA) has issued an alert regarding certain injection sites on the face where unintentional injection of soft tissue fillers into blood vessels in the face can result in rare but serious side effects.
Researchers at the NYU Langone Medical Center have reported that up to six percent of adults in New York who get tattoos have experienced some form of tattoo-related rash, severe itching, or swelling that lasted from four months up to years for some.
The Food and Drug Administration (FDA) has accepted for review the amended Biologics License Application (BLA) for Coagadex (coagulation factor X, human) for hereditary X deficiency.
The Food and Drug Administration (FDA) has approved Viberzi (eluxadoline; Actavis) and Xifaxan 550mg (rifaximin; Salix) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
A new RAND Corporation Study has shown that patients are more likely to be prescribed a broad-spectrum antibiotic for an acute respiratory infection by a doctor on a telephone or live video than face-to-face for the same illness.
Patients with multiple sclerosis (MS) may have twice the mortality risk compared to those without MS, despite research indicating that MS survival may be improving over time. The results from this study were published in the journal Neurology.
The National Association of Boards of Pharmacy (NABP) announced that the general availability for the .pharmacy domain will begin on June 3, 2015 for pharmacies and pharmacy-related entities.
Excessive inflammation that is present in multiple sclerosis (MS) may be due to a malfunctioning "brake" within immune cells to control the inflammation, researchers have concluded.
A study published in The BMJ suggests a link between newer contraceptive pills and higher risk of serious blood clots. The finding is not new, but it may be cause for a different kind of concern.
The Food and Drug Administration (FDA) has approved Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL [U-200]; Eli Lilly) to improve glycemic control in patients with type 1 and type 2 diabetes.
Actavis announced that it will continue to distribute Namenda (memantine HCI) tablets due to a recent decision by a panel of the U.S. Court of Appeals for the Second Circuit.
Results from a new study suggest that small controlled doses of carbon monoxide may protect the brain from damage after a subarachnoid hemorrhage by speeding up the clearance of heme that accumulates.
Researchers have created a DNA vaccine that may help reduce blood pressure for up to six months, new research published in the journal Hypertension has shown.
Novartis announced results from its Phase 3 EXPEDITION trial for indacaterol/glycopyrronium (QVA149) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
The Food and Drug Administration (FDA) has granted Orphan Drug designation to CRLX101 (Cerulean Pharma) for the treatment of ovarian cancer.
Very overweight male adolescents could have double the risk of developing bowel cancer later in life compared to those of normal weight, according to new research appearing in the journal Gut.
On May 25th, the Centers for Disease Control and Prevention (CDC) and the New Jersey Department of Health reported a death due to Lassa fever in a person returning to the United States from Liberia.
A new study published in JAMA has found that supplementation with soy isoflavone did not improve lung function or critical outcomes in patients with poor asthma control, despite previous research suggesting that it may be an effective treatment.
Par announced the launch of Cortisporin-TC (colistin sulfate, neomycin sulfate, thonzonium bromide, hydrocortisone acetate) Otic Suspension for the treatment of otitis externa caused by susceptible organisms and for the treatment of mastoidectomy and fenestration cavities caused by susceptible organisms.
Inhaled statins could become a novel class of inhaler therapy for airway diseases such as asthma, suggests a new study published in the journal Physiological Reports.
A genetic variant may be linked to a patient's likelihood of responding to interferon-beta therapy in multiple sclerosis (MS), according to a study published in the Annals of Neurology.
Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has approved Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Heart rate measures may help identify a person's future risk of diabetes, researchers have proposed.
A drug to treat stroke showed efficacy in treating middle-ear infections by suppressing mucus overproduction, improving bacterial clearance, and reducing hearing loss, researchers from the Georgia State University and University of Rochester reported.
Aptensio XR (methylphenidate HCl extended-release) capsules will be available starting Summer 2015 for the treatment of attention deficit hyperactivity disorder (ADHD).
Pfizer Consumer Healthcare announced the launch of Centrum MultiGummies, a multivitamin to help support energy, immunity, and metabolism.
Boehringer Ingelheim announced new data analyses from the Phase 3 TONADO 1&2 studies of tiotropium/olodaterol delivered via Respimat inhaler for chronic obstructive pulmonary disease (COPD).
Prolonged acetaminophen use (1 week) by pregnant women may suppress fetal testosterone production, according to researchers from the University of Edinburgh.
Regeneron and Sanofi announced results from their Phase 3 SARIL-RA-TARGET trial of sarilumab in patients with rheumatoid arthritis (RA).
Ampio Pharmaceuticals announced positive results from the OptimEyes Trial for Optina in patients with diabetic macular edema (DME).
Tris Pharma announced that the Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.
Infections may impair cognitive ability as measured on an IQ scale, data from a large study has shown.
The FDA is warning healthcare providers about the risk for dosing errors with Zerbaxa (ceftolozane and tazobactam; Cubist) due to confusion of the strength displayed on the vial and carton labeling.
Results from a large study show that people with depression may be more likely to develop Parkinson's disease.
Healthcare providers at hospitals and physicians' offices are in an important position to ensure consumers about food safety, Michael Doyle, a Regents Professor in the department of food science and technology at the University of Georgia reported.
New research in the Journal of Clinical Endocrinology & Metabolism supports previous findings that fetal sex may be associated with an increased risk of gestational diabetes mellitus (GDM) or subsequent type 2 diabetes diagnosis after pregnancy.
Scientists have developed a second generation antibiotic that has demonstrated early efficacy against common bacterial infections.
Osteo Bi-Flex announced the launch of Osteo Bi-Flex EASE, a mini-tab supplement that promotes joint comfort through a novel collagen-based formula.
A pathogen can develop resistance faster in a "pocket" of the body where only one drug is present compared to where no pockets exist, a new study published in the Proceedings of the National Academy of Sciences has shown.
Naltrexone could be a promising adjunct pharmacologic treatment for methamphetamine addiction, as it significantly reduced cue-induced cravings and subjective responses to methamphetamine in this first-of-its-kind study to be conducted in the United States.
Treatment with inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) may reduce the risk of death from pneumonia and other causes although they are associated an increased incidence of pneumonia, a meta-analysis presented at the 2015 American Thoracic Society International Conference has shown.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to revusiran (Alnylam) for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis).
Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has amended a previously granted Breakthrough Therapy designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients.
Sunovion announced new results from the first placebo-controlled study evaluating Latuda (lurasidone HCl) in adults with major depressive disorder (MDD) who presented with mixed (subsyndromal hypomanic) features.
In a study presented at Digestive Disease Week (DDW), non-prescription IBgard led to a reduction in symptoms associated with irritable bowel syndrome (IBS), including unbearable and severe symptoms and abdominal pain intensity.
An article in The Lancet Diabetes & Endocrinology reviews evidence on screening and treatment for depression in adult patients with type 1 and type 2 diabetes and issues recommendations on treating these comorbid conditions.
A short course of oral steroids provided modest improvement in function and no significant improvement in pain for patients with acute radiculopathy (sciatica), a study published in JAMA has shown.
Some plastic teethers for babies may contain endocrine disrupting chemicals, a new study has found.
Janssen announced that the Food and Drug Administration (FDA) has approved Invega Trinza (paliperidone palmitate) extended-release injectable suspension, the first and only medication indicated for the treatment of schizophrenia in adults that requires administration only four times per year and provides the longest dosing interval currently available.
A new study has shown that treatment for overactive bladder (OAB) may lead to less falls among older adults.
Astellas Pharma and Medivation announced data from the Phase 2 STRIVE trial comparing Xtandi (enzalutamide) and bicalutamide in non-metastatic (M0) and metastatic (M1) prostate cancer patients whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy of following surgical castration.
Astellas Pharma announced results from the Phase 3b BESIDE trial with solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy in incontinent overactive bladder (OAB) patients.
The Food and Drug Administration (FDA) has granted Fast Track designations to luspatercept (Celgene and Acceleron) for use in two separate indications: for the treatment of patients with transfusion dependent beta-thalassemia and for the treatment of patients with non-transfusion dependent beta-thalassemia.
Research supporting the neurological basis for fibromyalgia, a chronic central nervous system (CNS) disorder, was presented at the American Pain Society Annual Scientific Meeting.
Janssen announced data from three real-world analyses for Invokana (canagliflozin) in adults with type 2 diabetes.
The Food and Drug Administration (FDA) has issued a warning to healthcare providers on the purchasing of counterfeit, unapproved, or otherwise unsafe prescription drugs from unauthorized or unlicensed distributors.
Researchers presented key risk factors that can help identify patients at risk for acute exacerbations of their chronic obstructive pulmonary disease (COPD), at the 2015 American Thoracic Society International Conference.
Regular aspirin use is associated with a slower progression of early emphysema on computed tomography (CT) scans over the course of 10 years, according to research presented the 2015 American Thoracic Society International Conference.
Movantik (naloxegol; AstraZeneca) was found to have a similar incidence of adverse events among elderly patients as compared to placebo or usual care, safety analyses presented at Digestive Disease Week 2015 have shown.
Research suggests that a history of concussion with loss of consciousness may be associated with increased brain atrophy in the area involved with storing memory and impaired memory performance.
Endo announced that the Food and Drug Administration (FDA) has approved a label update for Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord.
Actavis announced that Namzaric (memantine HCl extended-release and donepezil HCl) capsules have launched for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine HCl and donepezil HCl.
A new policy statement from the American Thoracic Society provides guidance for crucial decision-making for intensive care patients while preventing conflicts between medical staff and family caregivers. The guideline appears in the American Journal of Respiratory and Critical Care Medicine.
Results from the SCALE Obesity and Pre-diabetes trial showed that adults who were early responders to Saxenda had greater weight loss after completing 56 weeks along with a reduced-calorie diet and increased physical activity vs. those who were early nonresponders.
New data presented at the American Geriatrics Society 2015 Annual Scientific meeting suggests that the rates of major bleeding and fatal outcomes in elderly patients with non-valvular atrial fibrillation (NVAF) treated with Xarelto (rivaroxaban; Janssen) are consistent with those reported in Phase 3 clinical trials.
Commonwealth announced the launch of IBSchek, a blood test to guide physicians in the diagnosis of irritable bowel syndrome (IBS).
The Food and Drug Administration (FDA) is warning that certain medications indicated for the treatment of type 2 diabetes may lead to ketoacidosis, the production of high levels of blood acids that could require hospitalization.
AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for Humira (adalimumab) as an investigational treatment for moderate-to-severe hidradenitis suppurativa (HS; Hurley Stage II and III disease).
A drug indicated for the treatment of type 2 diabetes improved metabolism and reduced inflammation in HIV-positive adults taking antiretroviral therapy, which could reduce the risk of cardiovascular disease and diabetes due to chronic inflammation.
Janssen and Bayer HealthCare announced results from the VENTURE-AF trial that compared Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKA) to reduce the risk of blood clots in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation.
Pernix announced that the Food and Drug Administration (FDA) has approved Treximet (sumatriptan, naproxen sodium) for use in pediatric patients aged 12 and older for the acute treatment of migraine with or without aura.
An analysis performed by researchers at the Celiac Disease Center at Columbia University Medical Center shows that more than half of popular probiotics contain traces of gluten.
A recent review compared published data from 67 articles on the efficacy of diclofenac, ketorolac, flurbiprofen, bromfenac, and nepafenac within and outside their FDA-approved uses.
A study presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting found that an over-the-counter form of vitamin B3 significantly reduced rates of new non-melanoma skin cancers in high-risk patients, which along with sun protection could help to decrease the health and economic burden of skin cancer.
Infants that receive regional anesthesia vs. general anesthesia for surgery may have better recovery, data from two studies have shown.
Scientists at the University of Minnesota have created a predictive model for measuring healthy development of bacteria in the gut of young children and a framework to map potential links between antibiotics, gut bacteria, and disease later in life.
New research published in The Lancet suggests that testing grip strength could be a quick, low-cost screening tool for clinicians to identify patients at a greater risk of mortality due to cardiovascular and non-cardiovascular disease (such as cancer).
The Food and Drug Administration (FDA) has denied a Citizen Petition requesting the initiation of a rulemaking to change a tobacco warning statement required on smokeless tobacco products.
While the potential relationship between stress and cancer has been a topic of discussion and research for over 70 years, no association between post-traumatic stress disorder (PTSD) and cancer was found in the largest study to date and published in the European Journal of Epidemiology.
Purdue announced data from a long-term safety and efficacy study of Hysingla ER (hydrocodone bitartrate extended-release) tablets with abuse-deterrent properties.
Vertex announced that the Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 12 to 1 to recommend that the FDA approve Orkambi (lumacaftor/ivacaftor) for people with cystic fibrosis (CF) aged 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
About 240 million people have an alcohol use disorder and over one billion people smoke tobacco, according to a new study published in the journal Addiction.
The Food and Drug Administration (FDA) has issued a draft guidance for blood establishments that collect blood or blood components with recommended revisions to the donor deferral period for men who have sex with men (MSM).
Researchers have established a new defense mechanism to explain how Escherichia coli can thrive during flare ups in patients with inflammatory bowel disease (IBD).
A new study in JAMA reports that a significant reduction in the rate of dispensing of codeine to postpartum women was observed following public health advisories from the U.S. Food and Drug Administration (FDA) and Health Canada on potentially life-threatening adverse effects in infants of breastfeeding mothers taking codeine.
The Food and Drug Administration (FDA) has granted Fast Track status to evofosfamide (Merck KGaA) in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.
A study by the Centers for Disease Control and Prevention (CDC) and Cedars-Sinai proposes that the 9-valent human papillomavirus (HPV) vaccine could prevent 80 percent of cervical cancers in the United States if administered to all 11- or 12-year-old children prior to exposure to the virus.
Takeda and Orexigen announced the early termination of the Light Study, a cardiovascular (CV) outcomes trial following the recommendation of the Executive Steering Committee (ESC).
A simple electronic reminder during an office visit may encourage more patients to get the human papillomavirus (HPV) vaccine to protect against cervical cancer, researchers have found.
Nevro announced that the Food and Drug Administration (FDA) has approved the Senza System, a spinal cord stimulation (SCS) system as an aid in the management of chronic intractable pain of the trunk and/or limbs, including pain associated with failed back surgery syndrome, low back pain, and leg pain.
- McDonald's and the Microbiome: What Effect Does Junk Food Have on Gut Bacteria?
- When the Doctor is Depressed: One Clinician Tells His Story
- Most Distinctive Causes of Death Mapped by U.S. State
- Spice + Statin Likely Culprit in Patient with Acute Hepatitis
- First Non-Surgical Tx for "Double Chin" Gains FDA Approval